Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (MRCC): Bevacizumab (B) plus Immunotherapy (I) plus Chemotherapy (C) (BIC). Antitumor effects and variations of circulating T-regulatory cells (Treg) and other T lymphocytes subsets / Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Dalla Chiesa, M; Tomasello, G; Negri, F; Lazzarelli, S. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 20:(2009), pp. viii80-viii80.

Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (MRCC): Bevacizumab (B) plus Immunotherapy (I) plus Chemotherapy (C) (BIC). Antitumor effects and variations of circulating T-regulatory cells (Treg) and other T lymphocytes subsets

Buti S;
2009

Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (MRCC): Bevacizumab (B) plus Immunotherapy (I) plus Chemotherapy (C) (BIC). Antitumor effects and variations of circulating T-regulatory cells (Treg) and other T lymphocytes subsets / Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Dalla Chiesa, M; Tomasello, G; Negri, F; Lazzarelli, S. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 20:(2009), pp. viii80-viii80.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2906887
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact